Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

About this update from Novocure Limited

[{"type":"text","content":"\nFinal data from the PANOVA-3 study anticipated in 2024 \n\n ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer.\n\n“There is a severe unmet need for patients with pancreatic cancer,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Each year in the U.S. alone, approximately 43,000 people are diagnosed with unresectable pancreatic cancer; however, the five-year survival rate remains stagnant at just 10%. The completion of the PANOVA-3 study marks a critical milestone for our company and potentially for patients suffering from this deadly disease. We are proud to be adding to the evolving clinical research and are excited at the prospect of improving patient survival.”\n\nFollowing the completion of enrollment, an independent Data Monitoring Committee will conduct a pre-specified interim analysis pursuant to the trial protocol. Patients will be followed for a minimum of 18 months.\n\nPANOVA-3 is a randomized, open-label study which was designed to enroll 556 adult patients with unresectable, locally advanced pancreatic adenocarcinoma. Patients have been randomized to receive either the combination of nab-paclitaxel and gemcitabine alone or the combination of nab-paclitaxel and gemcitabine concomitant with TTFields tuned to 150 kHz until progression. The primary endpoint is overall survival. Secondary endpoints are progression free survival, local progression free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity.\n\nAbout Pancreatic Cancer\n\nPancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the U.S. While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing. It is estimated that approximately 53,000 patients are diagnosed with pancreatic cancer each year in the U.S. Pancreatic cancer has a five-year relative survival rate of just 10%.\n\nPhysicians use different combinations of surgery, radiation and phar...

More updates from Novocure Limited